Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Alejandro Sweet-Cordero

Showing results (21-30 of 66) with videos related to

Pageof 7
Sort By:
Journal of Pediatric Hematology/Oncology|August 21, 2020
NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMMLAstrid Behnert, Alex G Lee, Elizabeth P Young, et al.
Cancer Discovery|October 2, 2025
Epigenetic and transcriptional programs define osteosarcoma subtypes and establish targetable vulnerabilitiesEunice Lopez-Fuentes, Andrew S Clugston, Alex G Lee, et al.
Cancer Reports (Hoboken, N.J.)|November 7, 2023
Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patientsSavannah S Shumock, William C Temple, Amanda Marinoff, et al.
Cancer Cell|January 10, 2018
Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-AsparaginaseDana M Gwinn, Alex G Lee, Marcela Briones-Martin-Del-Campo, et al.
Molecular & Cellular Proteomics : MCP|May 20, 2022
Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine StimulationPaige E Solomon, Lisa L Kirkemo, Gary M Wilson, et al.
Cancer Cell|May 7, 2016
An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-SufficiencyJennifer J Brady, Chen-Hua Chuang, Peyton G Greenside, et al.
Pediatric Blood & Cancer|April 20, 2017
Improvement in treatment abandonment in pediatric patients with cancer in GuatemalaElysia Alvarez, Midori Seppa, Silvia Rivas, et al.
Nature Communications|July 5, 2023
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinomaKaja Kostyrko, Marta Román, Alex G Lee, et al.
Cancer Discovery|July 31, 2020
Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and SusceptibilitiesMarcus R Kelly, Kaja Kostyrko, Kyuho Han, et al.
The Journal of Clinical Investigation|October 26, 2010
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human modelsSilvestre Vicent, Ron Chen, Leanne C Sayles, et al.
Pageof 7

Showing results (21-30 of 66) with videos related to

Sort By:
Pageof 7
Journal of Pediatric Hematology/Oncology|August 21, 2020
NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMMLAstrid Behnert, Alex G Lee, Elizabeth P Young, et al.
Cancer Discovery|October 2, 2025
Epigenetic and transcriptional programs define osteosarcoma subtypes and establish targetable vulnerabilitiesEunice Lopez-Fuentes, Andrew S Clugston, Alex G Lee, et al.
Cancer Reports (Hoboken, N.J.)|November 7, 2023
Pre-and post-HSCT use of TKI therapy for fusion-driven B-ALL: A case series of five pediatric, adolescent and young adult patientsSavannah S Shumock, William C Temple, Amanda Marinoff, et al.
Cancer Cell|January 10, 2018
Oncogenic KRAS Regulates Amino Acid Homeostasis and Asparagine Biosynthesis via ATF4 and Alters Sensitivity to L-AsparaginaseDana M Gwinn, Alex G Lee, Marcela Briones-Martin-Del-Campo, et al.
Molecular & Cellular Proteomics : MCP|May 20, 2022
Discovery Proteomics Analysis Determines That Driver Oncogenes Suppress Antiviral Defense Pathways Through Reduction in Interferon-β Autocrine StimulationPaige E Solomon, Lisa L Kirkemo, Gary M Wilson, et al.
Cancer Cell|May 7, 2016
An Arntl2-Driven Secretome Enables Lung Adenocarcinoma Metastatic Self-SufficiencyJennifer J Brady, Chen-Hua Chuang, Peyton G Greenside, et al.
Pediatric Blood & Cancer|April 20, 2017
Improvement in treatment abandonment in pediatric patients with cancer in GuatemalaElysia Alvarez, Midori Seppa, Silvia Rivas, et al.
Nature Communications|July 5, 2023
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinomaKaja Kostyrko, Marta Román, Alex G Lee, et al.
Cancer Discovery|July 31, 2020
Combined Proteomic and Genetic Interaction Mapping Reveals New RAS Effector Pathways and SusceptibilitiesMarcus R Kelly, Kaja Kostyrko, Kyuho Han, et al.
The Journal of Clinical Investigation|October 26, 2010
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human modelsSilvestre Vicent, Ron Chen, Leanne C Sayles, et al.
Pageof 7